CU6 Archives - ShareCafe

Clarity Pharmaceuticals (ASX:CU6) has developed a novel radiopharmaceutical called "SAR-bisFAP", a product that could be used for both diagnosis and treatment, with "pan-cancer" applicability.

FNN Content / Shares

Clarity Pharmaceuticals achieves milestones in prostate cancer trial

October 16, 2024 - by Finance News Network

Clarity Pharmaceuticals (ASX:CU6) has reported significant developments in its SECuRE trial.

Markets / Shares / Video

Clarity Pharmaceuticals (ASX: CU6) – webinar presentation

December 5, 2022 - by Company News

Dr Alan Taylor – Executive Chairperson – Clarity’s mission is to develop next-generation radiopharmaceutical products that improve treatment outcomes for children and adults with cancer.